Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma - European Medical Journal

Phase 2 trial of lenvatinib and everolimus in metastatic renal cell carcinoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London, UK, discusses the results of a phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally

>